Actionable news
All posts from Actionable news
Actionable news in EGLT: EGALET CORPORATION,

Blog Coverage Egalet Announced Positive Results from Human Abuse Potential Study of Egalet-002

Dec 19, 2016 (ACCESSWIRE via COMTEX) -- Upcoming AWS Coverage on Foamix Pharma Post-Earnings Results

LONDON, UK / ACCESSWIRE / December 19, 2016 / Active Wall St. blog coverage looks at the headline from Egalet Corp. EGLT, +12.55% as the Company announced on December 16, 2016, positive top-line results from a Category 3 intranasal human abuse potential (HAP) study of Egalet-002, an abuse-deterrent, extended-release oxycodone product candidate. Register with us now for your free membership and blog access at:

One of Egalet's competitors within the Biotechnology space, Foamix Pharmaceuticals Ltd. FOMX, +1.30% reported on November 16, 2016, its financial results for the three and nine months ended September 30, 2016. AWS will be initiating a research report on Foamix Pharma in the coming days.

Today, AWS is promoting its blog coverage on EGLT; touching on FOMX. Get all of our free blog coverage and more by clicking on the links below:

Egalet-002 is in late-stage development for the management of pain severe enough to require daily around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet-002 was designed using a version of Egalet's proprietary Guardian Technology that contains an inner matrix and an exterior shell.

Egalet - 002 Study Results

The HAP study of Egalet - 002 was a randomized, double-blind, active and placebo-controlled 6-period crossover study. The study evaluated the abuse potential of manipulated Egalet-002 compared to crushed immediate-release (IR) oxycodone through the nasal route in 46 non-dependent recreational opioid users experienced in nasal insufflation. A comparison to manipulated OxyContin® was also included as an exploratory arm. The study was conducted in accordance with the FDA's Guidance for Industry, Abuse-Deterrent Opioids - Evaluation and Labeling.

The treatment periods included Egalet-002 40 mg (manipulated with shell on), Egalet-002 40 mg (with shell taken off), crushed IR oxycodone 40 mg, manipulated OxyContin 40 mg, manipulated Egalet-002 placebo tablet, and placebo powder.

For the primary comparison, the difference in maximum Drug Liking (Emax) between manipulated Egalet-002 (with shell on) was significantly lower compared to crushed IR oxycodone with p = 0.0004. The outcome was also significant for the comparison between manipulated Egalet-002 (with shell off) and crushed IR oxycodone with p < 0.0001.

For the secondary outcome of Take Drug Again, the results were 69.9 for manipulated Egalet-002 (shell on), 72.4 for manipulated Egalet-002 (shell off), and 75.5 for crushed IR oxycodone; not statistically significant for either comparison.

In the exploratory analysis with OxyContin, Emax Drug Liking was...